Tracers / [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1
[225Ac]Ac-Macropa-pertuzumab-PEG6-DM1
Also written as [Ac-225]Ac-Macropa-pertuzumab-PEG6-DM1
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- Antibody-drug radioconjugate (anti-HER2 antibody-drug conjugate labeled with actinium-225)
- Target / mechanism
- HER2 (human epidermal growth factor receptor 2) PMID 41946831
- Clinical application
- Radioimmunotherapy of HER2-positive breast cancer, including trastuzumab/T-DM1-resistant tumours PMID 41946831
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | Macropa-pertuzumab-PEG6-DM1 | 41946831 2026 Br J Cancer |
Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41946831. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41946831: 'Radioimmunotherapy was done in nude mice bearing trastuzumab-resistant HCC1954 (high HER2-density), T-DM1/trastuzumab-resistant JIMT-1 (medium HER2-density) and MDA-MB-468 (negative control with very low HER2-density) xenografts.'.